Skip to main content

Table 2 Cumulative incidence and hazard ratio of Alzheimer’s disease between groups

From: Impact of nucleos(t)ide analogue therapy on the incidence of Alzheimer’s disease in patients with chronic hepatitis B virus infection

  

Simple competing

risk model

Multiple competing

risk model**

Propensity score-

matched model

Year

NUC

Treatment

group

Cumulative

Incidence (95% CI)

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

2

NUC (-)

0.0002 (0.0002–0.0003)

1.00

 

1.00

 

1.00

 

NUC (+)

0.0001 (0 − 0.0004)

0.46 (0.11–1.91)

0.286

0.51 (0.12–2.05)

0.339

0.40 (0.08–2.06)

0.273

3

NUC (-)

0.0004 (0.0003–0.0005)

1.00

 

1.00

 

1.00

 

NUC (+)

0.0002 (0–0.0005)

0.44 (0.14–1.38)

0.156

0.55 (0.18–1.69)

0.294

0.43 (0.11–1.66)

0.220

4

NUC (-)

0.0006 (0.0005–0.0007)

1.00

 

1.00

 

1.00

 

NUC (+)

0.0002 (0.0001–0.0005)

0.37 (0.14-1.00)

0.051

0.51 (0.19–1.39)

0.187

0.36 (0.12–1.14)

0.083

5

NUC (-)

0.0009 (0.0008–0.0010)

1.00

 

1.00

 

1.00

 

NUC (+)

0.0003 (0.0001–0.0006)

0.31 (0.13–0.75)

0.009

0.41 (0.17-1.00)

0.049

0.33 (0.12–0.92)

0.033

6

NUC (-)

0.0012 (0.0011–0.0013)

1.00

 

1.00

 

1.00

 

NUC (+)

0.0005 (0.0002–0.0009)

0.41 (0.21–0.80)

0.009

0.55 (0.28–1.07)

0.079

0.41 (0.19–0.89)

0.024

7

NUC (-)

0.0015 (0.0013–0.0017)

1.00

 

1.00

 

1.00

 

NUC (+)

0.0006 (0.0003–0.0011)

0.40 (0.22–0.73)

0.003

0.54 (0.29–0.99)

0.045

0.38 (0.19–0.76)

0.006

  1. Abbreviations: HR, hazard ratio; CI, confidence interval, NUC, nucleos(t)ide analogue
  2. ** Adjusted: age, sex, Socioeconomic status, cirrhosis, level of health care, diabetes mellitus, hypertension, dyslipidemia, chronic kidney disease, congestive heart failure, ischemic heart disease, and traumatic brain injury